PKC-dependent APP modulators remain highly attractive strategies for AD therapy because of their high potency, specificity, low potential for carcinogenesis, and high anti-inflammatory potential (Carpenter and Alexander 2008). The gene discussed is PRRT2; the disease is Alzheimer disease.